King Penicillin Faces Production Delays
This article was originally published in The Pink Sheet Daily
Executive Summary
Supply of King Pharmaceuticals' Bicillin L-A (penicillin G benzathine) injection will be maintained despite a shortage of the drug, according to a May 22 notice posted on FDA's website
You may also be interested in...
King “Dear Doctor” Letter Warns Against Bicillin C-R Use For Syphilis
Bicillin C-R should not be used to treat syphilis, King says in letter spurred by reports of misuse; Bicillin L-A is the only penicillin G benzathine product indicated for syphilis. A “black box” has been added to both products to emphasize intramuscular injection as only route of administration.
Future BIO Global Efforts Include International Relations, Greenwood Says
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13
Hospira’s Mayne Event: Acquisition Strengthens Oncology Portfolio
Merger will create the leading generic injectable pharmaceutical company in the world.